4.6 Review

Musashi-1-A Stemness RBP for Cancer Therapy?

Journal

BIOLOGY-BASEL
Volume 10, Issue 5, Pages -

Publisher

MDPI
DOI: 10.3390/biology10050407

Keywords

RNA– binding protein; musashi– 1; MSI1; stemness; cancer; cell cycle; signaling

Categories

Funding

  1. Wilhelm-Roux Program (Martin Luther University Halle/Wittenberg)
  2. EU
  3. DFG [GRK1591]

Ask authors/readers for more resources

The RNA-binding protein Musashi-1 (MSI1) plays a crucial role in promoting stemness properties during development and in cancer, contributing to cancer growth and therapy resistance. MSI1's specific expression pattern and diverse functions make it an interesting target for future cancer therapy, with current research focusing on MSI1-directed inhibitors with anti-tumor activity.
Simple Summary Musashi-1 (MSI1) is an RNA-binding protein that promotes stemness properties. It was initially discovered as a regulator of neuronal development and oocyte maturation in flies and frogs. Due to its specific expression pattern with high levels during development and in a variety of cancers, MSI1 evolved as an interesting target for cancer therapy. In cancer cells, the protein mainly promotes an undifferentiated state enhancing cancer growth and therapy resistance. In this review, we summarize previous findings from development of other organisms, outline MSI1 ' s expression and function in different cancer entities and highlight the development of MSI1-directed inhibitors. The RNA-binding protein Musashi-1 (MSI1) promotes stemness during development and cancer. By controlling target mRNA turnover and translation, MSI1 is implicated in the regulation of cancer hallmarks such as cell cycle or Notch signaling. Thereby, the protein enhanced cancer growth and therapy resistance to standard regimes. Due to its specific expression pattern and diverse functions, MSI1 represents an interesting target for cancer therapy in the future. In this review we summarize previous findings on MSI1 ' s implications in developmental processes of other organisms. We revisit MSI1 ' s expression in a set of solid cancers, describe mechanistic details and implications in MSI1 associated cancer hallmark pathways and highlight current research in drug development identifying the first MSI1-directed inhibitors with anti-tumor activity.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available